Related Experiment Video
Updated: Jan 15, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer
Pengfei Xu1, Huan Qu1, Joy C Yang1
1Department of Urologic Surgery, School of Medicine, University of California, Davis, CA 95817, USA.
Background:
Treatment with androgen receptor (AR) signaling inhibitors, such as enzalutamide, can induce neural lineage plasticity in prostate cancer, potentially progressing to t-NEPC. However, the molecular mechanisms underlying this enzalutamide-driven plasticity, particularly the contribution of immune signaling pathways, remain poorly understood.
Methods:
We analyzed transcriptomic profiles of patient samples and prostate cancer cell lines to investigate changes in immune signaling pathways. Interferon gamma (IFNγ), interferon alpha (IFNα), and interleukin 6 (IL6)-Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) signaling were assessed in enzalutamide-sensitive and -resistant prostate cancer cells. Functional assays were conducted to examine cell responsiveness to cytokine stimulation and susceptibility to STAT1 inhibition using fludarabine.
Results:
Immune-related pathways, including IFNγ, IFNα, IL6-JAK-STAT3, and inflammatory responses, were significantly suppressed in NEPC patient samples compared to those with castration-resistant prostate cancer (CRPC). Enzalutamide-resistant and NEPC cells exhibited markedly impaired IFNγ and IL6 signaling. In contrast, early-stage enzalutamide treatment paradoxically enhanced IFNγ and IL6 responsiveness. Transcriptomic profiling revealed coordinated upregulation of E2F target genes and activation of IFNα/IFNγ and JAK/STAT signaling pathways during early treatment. Importantly, these early-stage cells remained highly sensitive to IFNγ and IL6 stimulation and showed increased susceptibility to STAT1 inhibition by fludarabine, a sensitivity that was lost in resistant cells.
Conclusions:
Early enzalutamide treatment enhances immune responsiveness, while the development of resistance is associated with suppressed immune signaling and increased lineage plasticity. These results suggest a therapeutic window where combining enzalutamide with STAT inhibitors may delay or prevent lineage plasticity and resistance.
Insights
Early enzalutamide treatment boosts immune response in prostate cancer, but resistance leads to suppressed immunity and plasticity. Combining enzalutamide with STAT inhibitors may prevent resistance.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Androgen receptor (AR) inhibitors like enzalutamide can drive prostate cancer to neuroendocrine prostate cancer (NEPC).
- The role of immune signaling in enzalutamide-induced lineage plasticity is not well understood.
Purpose of the Study:
- To investigate the impact of enzalutamide on immune signaling pathways during prostate cancer progression.
- To explore the potential of targeting immune pathways to overcome enzalutamide resistance and lineage plasticity.
Main Methods:
- Transcriptomic analysis of patient samples and cell lines.
- Assessment of interferon (IFN) and interleukin (IL) signaling pathways (IFNγ, IFNα, IL6-JAK-STAT3).
- Functional assays evaluating cytokine response and STAT1 inhibition with fludarabine.
Main Results:
- Immune pathways (IFNγ, IFNα, IL6-JAK-STAT3) were suppressed in NEPC and enzalutamide-resistant cells.
- Early enzalutamide treatment enhanced IFNγ and IL6 responsiveness and activated JAK/STAT signaling.
- Early-stage cells showed sensitivity to STAT1 inhibition, which was lost in resistant cells.
Conclusions:
- Enzalutamide initially enhances immune response but resistance involves immune suppression and plasticity.
- A therapeutic window exists for combining enzalutamide with STAT inhibitors to prevent resistance and plasticity.
More Related Videos
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
Treatment Resistant Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...